查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012614

化合物管理市場：2026-2032年全球市場預測（依最終用戶、化合物類型、應用和自動化程度分類）

Compound Management Market by End User, Compound Type, Application, Automation Level - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，複合管理市場價值將達到 14.5 億美元，到 2026 年將成長到 17.1 億美元，到 2032 年將達到 44.5 億美元，複合年成長率為 17.28%。

主要市場統計數據
基準年 2025 14.5億美元
預計年份：2026年 17.1億美元
預測年份 2032 44.5億美元
複合年成長率 (%) 17.28%

本文簡要概述了化合物管理的發展現狀，重點在於重組實驗室工作流程的技術、材料和操作方面的挑戰。

目前化合物管理的現狀是高通量科學、精準操作以及日益複雜的供應鏈動態三者交匯融合的結果。自動化、樣品完整性監控和數位化庫存管理等領域的最新技術進步，重新定義了科研機構和商業性研發部門對準確性、速度和可追溯性的期望。同時，隨著治療方法朝向生物製藥、細胞和基因療法的轉變，傳統平台無法充分滿足新的物料處理需求，亟需專門設計的解決方案。

自動化、生物製藥的複雜性以及數據驅動的互通性如何將化合物管理重新定義為策略性實驗室職能。

在技​​術和科學趨勢融合的驅動下，化合物管理領域正經歷著變革性的轉變。自動化不再局限於機械化，而是發展成為整合化的工作流程，其中機器人、環境控制系統和實驗室資訊管理系統能夠無縫協作。這種整合降低了人工干預和錯誤率，並實現了可擴展的樣品處理能力，同時也提升了系統互通性和供應商協作的重要性。同時，複雜生物製藥、基因療法和細胞衍生產品的興起，對儲存、處理和可追溯性提出了新的要求，而傳統的以小分子為中心的系統無法滿足這些要求。

應對營運和採購中的關稅波動，正在重塑研究機構的供應商策略、庫存管理實踐和國際合作。

2025年推出的關稅政策趨勢正在對採購、合約簽訂和跨國科研合作等各個領域造成實際壓力。某些實驗室設備、耗材和化學品的進口關稅提高，迫使許多機構重新評估其供應商組合併重新談判契約，以維持營運的連續性。因此，採購團隊正與科學研究部門負責人更緊密合作，優先儲備關鍵物資，探索替代供應商，並選擇區域分銷商，以降低對單一供應商的依賴風險。

基於詳細細分的洞察，揭示了每個最終用戶、化合物類型、應用和自動化層級的不同需求，從而指導策略性產品和服務的最佳化。

細分市場洞察揭示了不同的需求和部署模式，這些模式都應指南產品開發、服務模式和市場策略。從最終用戶的觀點來看，學術和研究機構通常優先考慮柔軟性、成本效益以及與各種儀器的開放式整合，而製藥公司則尋求檢驗、擴充性且具有強大合規能力並致力於長期服務交付的系統。生技公司通常需要能夠適應專案範圍快速變化的模組化解決方案，而受託研究機構(CRO) 則優先考慮高通量能力和標準化工作流程，以服務多個客戶。政府和監管機構則強調用於監測和公共衛生研究的樣本的監管鍊和長期存檔完整性。

區域科學生態系統和法規環境如何影響全球市場中化合物管理重點、支援模式和自動化採用。

區域趨勢影響企業在化合物管理方面對投資、夥伴關係和營運韌性的優先順序。美洲地區集中了許多大規模製藥研發中心和成熟的生物技術生態系統，推動了對高通量、檢驗的系統和服務模式的需求，以支持受監管的研發。該地區還擁有活躍的整合服務和本地化支援網路的售後市場，促使供應商提供長期服務合約和客製化方案。歐洲、中東和非洲（EMEA）地區呈現出多元化的環境，跨國公司與國家研究機構和新興生物技術企業並肩運作。歐洲部分地區的監管協調與其它地區特定的採購規則形成鮮明對比，影響自動化和先進庫存管理系統的採用曲線。在該地區，需要在跨境合作和當地監管限制之間取得平衡，這凸顯了企業對合規模組化解決方案的濃厚興趣。

競爭與夥伴關係趨勢揭示了硬體、軟體和服務的整合，以及以應用為中心的創新，如何塑造供應商差異化和客戶維繫。

對主要企業的分析著重於策略定位、夥伴關係模式以及差異化優勢顯著的領域。市場領導憑藉著強大的硬體產品組合、擴充性的軟體平台和成熟的服務交付能力，最能贏得需要長期檢驗和運作保證的企業級專案。同時，新興供應商透過提供模組化、可升級的架構，降低了中型檢查室的自動化門檻，並透過開放API強調互通性，從而促進與實驗室資訊管理系統（LIMS）的整合，並因此獲得了市場認可。隨著企業努力提供提案安裝、檢驗、維護和資料管理的端到端夥伴關係，設備製造商、軟體供應商和第三方服務機構之間的策略合作夥伴關係日益普遍。

為高階主管提供可操作的策略重點，以增強複合管理環境中的互通性、供應鏈彈性和數據驅動營運。

產業領導者應採取果斷行動，使化合物管理能力與科學策略和營運韌性保持一致。首先，高階主管在評估新設備時應優先考慮互通性和模組化，確保投資能夠隨著科學重點的變化而擴展或重新利用。其次，應建立包括採購、科學研究營運、品質和IT在內的跨職能管治架構，以簡化供應商合格、管理價格和供應鏈風險並執行資料完整性標準。第三，各組織應試點利用分析和物聯網驅動的診斷能力開展數據驅動型舉措，以減少意外停機時間並最佳化試劑利用率，從而在提高產量的同時降低營運風險。

透過嚴謹的混合方法，結合對從業者的訪談、技術文獻的審查和專家檢驗，獲得了切實可行的操作見解和策略建議。

本執行摘要的調查方法結合了第一手資料和第二手資料，系統地審查了這兩類信息，以確保其相關性和實用性。一級資訊來源包括對學術機構、生物技術公司、受託研究機構、政府機構和製藥公司的實驗室經理、檢查室經理和技術負責人的訪談，從而直接了解實際操作中的挑戰和採購實踐。第二手資料包括供應商的技術文獻（說明了小分子化合物和複雜生物製藥處理要求的演變）、監管指導文件、同行評審文章以及關於自動化和資料整合最佳實踐的白皮書。

一項具有前瞻性的綜合分析，解釋了為什麼化合物管理是研發機構提高研究速度、樣品完整性和監管準備度的策略促進因素。

總之，化合物管理已從一項主要由行政部門主導的後勤部門職能發展成為一項策略能力，對調查速度、資料完整性和監管準備有顯著影響。自動化技術的進步、生物製藥和細胞/基因療法日益成長的重要性，以及對數據驅動的維護和庫存管理的日益重視，都促進了系統互通性、環境管理和服務可靠性標準的提升。積極整合採購、科研營運和IT職能的機構將更有利於最大限度地發揮現代化合物管理系統帶來的生產力提升，並降低供應鏈波動和監管審查帶來的風險。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：化合物管理市場：依最終用戶分類

  • 學術和研究機構
  • 生技公司
  • 合約研究機構
  • 政府/監管機構
  • 製藥公司

第9章：依化合物類型分類的化合物管理市場

  • 生技藥品
    • 細胞治療產品
    • 基因治療產品
    • 單株抗體
    • 重組蛋白
    • 疫苗
  • 核苷酸
  • 胜肽
  • 低分子化合物

第10章：化合物管理市場：依應用分類

  • 殺蟲劑
  • 藥物發現
    • 命中識別
    • 先導藥物最適化
    • 臨床前研究
    • 目標檢驗
  • 材料科學
  • 特種化學品

第11章：化合物管理市場：依自動化程度分類

  • 全自動系統
  • 手動系統
  • 半自動系統

第12章：複合管理市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：複合管理市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：複合管理市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國複合管理市場

第16章：中國複合管理市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agilent Technologies, Inc.
  • Arctoris Ltd.
  • AXXAM SpA
  • Azenta US, Inc.
  • Beckman Coulter Life Sciences
  • BioAscent Discovery Ltd.
  • BioIVT
  • Biosero Inc.
  • Brooks Automation, Inc.
  • ChemBridge Corporation
  • ChemDiv Inc.
  • Collaborative Drug Discovery
  • Compound Management Group
  • Danaher Corporation
  • Evotec SE
  • Hamilton Company
  • HighRes Biosolutions Inc.
  • Labcyte Inc.
  • LiCONiC AG
  • OpenEye Scientific Software, Inc.
  • PerkinElmer, Inc.
  • SPT Labtech Ltd.
  • Tecan Group Ltd.
  • Titian Service Limited
  • Wuxi AppTec Co., Ltd.
Product Code: MRR-436BDB26AFD9

The Compound Management Market was valued at USD 1.45 billion in 2025 and is projected to grow to USD 1.71 billion in 2026, with a CAGR of 17.28%, reaching USD 4.45 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.45 billion
Estimated Year [2026] USD 1.71 billion
Forecast Year [2032] USD 4.45 billion
CAGR (%) 17.28%

A concise framing of the evolving compound management landscape emphasizing technological, material, and operational pressures reshaping laboratory workflows

The compound management landscape sits at the intersection of high-throughput science, precision handling, and increasingly complex supply chain dynamics. Recent technological advances in automation, sample integrity monitoring, and digital inventory control have redefined expectations for accuracy, speed, and traceability across research organizations and commercial R&D. At the same time, shifts in therapeutic modalities toward biologics and cell and gene therapies have introduced new material handling requirements that challenge legacy platforms and demand purpose-built solutions.

Consequently, leaders must reconcile the need for robust, compliant compound custody with pressures to increase throughput and lower operational risk. This introduction synthesizes the forces reshaping compound management, clarifies where value is being created, and frames the strategic questions organizational leaders should prioritize. By establishing a shared baseline, decision-makers can evaluate technology investments, partnerships, and process redesigns with greater confidence and align compound handling capabilities to broader scientific and regulatory objectives.

How automation, biologics complexity, and data-driven interoperability are redefining compound management as a strategic laboratory capability

The landscape for compound management is undergoing transformative shifts driven by converging technological and scientific trends. Automation is maturing beyond mechanization into integrated workflows where robotics, environmental controls, and laboratory information management systems operate as a synchronized whole. This integration reduces manual touchpoints and error rates while enabling scalable sample throughput, yet it also increases the importance of systems interoperability and vendor collaboration. Simultaneously, the rise of complex biologics, gene therapies, and cell-based products imposes new storage, handling, and traceability requirements that legacy small-molecule-focused systems were not designed to satisfy.

In parallel, data-centric approaches are changing how organizations manage compound inventories. Advanced analytics and predictive maintenance improve uptime and reduce reagent waste, and digital audit trails enhance regulatory readiness. Moreover, partnerships between instrument manufacturers and software providers are accelerating the pace at which laboratories can adopt modular, upgradeable systems. Taken together, these shifts mean that compound management is no longer a back-office function; it is a strategic capability that underpins faster, safer, and more cost-effective research pipelines.

Operational and procurement responses to tariff shifts that are reshaping supplier strategies, inventory practices, and international collaboration in laboratories

Tariff dynamics introduced in 2025 have created tangible pressures across procurement, contract operations, and cross-border research collaborations. Elevated duties on specific laboratory equipment, consumables, and chemical imports have prompted many organizations to re-evaluate supplier portfolios and renegotiate contracts to preserve continuity of operations. As a result, procurement teams are working more closely with scientific leads to prioritize critical items for stockpiling, explore alternative suppliers, and qualify regional distributors to mitigate single-source exposure.

At the operational level, some laboratories have adjusted maintenance and calibration schedules to optimize the lifecycle of existing instruments and avoid immediate capital replacement during periods of higher import costs. In addition, greater emphasis is being placed on localization of critical supplies and on building strategic inventory buffers for reagents and consumables. International collaborations face added administrative burdens as customs classifications and compliance checks have increased lead times. In response, institutions are strengthening supply chain governance, enhancing demand forecasting practices, and pursuing contractual terms that share tariff risk between buyers and suppliers to sustain research continuity.

Deep segmentation-driven insights that illuminate distinct requirements across end users, compound types, applications, and automation levels to guide strategic product and service alignment

Segmentation insights reveal differentiated needs and adoption patterns that should guide product development, service models, and go-to-market approaches. When viewed through the lens of end users, academic and research institutions typically prioritize flexibility, cost-effectiveness, and open integration with diverse instrument fleets, whereas pharmaceutical companies demand validated, scalable systems with rigorous compliance features and long-term service commitments. Biotech companies often seek modular solutions that can accommodate rapid pivots in project scope, while contract research organizations focus on high-throughput capacity and standardized workflows to serve multiple clients. Government and regulatory agencies emphasize chain-of-custody and long-term archival integrity for samples used in surveillance and public health research.

Analyzing compound type highlights further nuances: small molecules generally benefit from established, high-density storage and automated retrieval systems, while biologics require specialized temperature control and contamination prevention; within biologics, cell therapy products, gene therapy products, monoclonal antibodies, recombinant proteins, and vaccines each present unique handling and regulatory demands that influence container formats, cold chain protocols, and validation pathways. Application-based segmentation shows that use cases such as agrochemicals and material science have different throughput and environmental tolerance requirements compared with drug discovery activities; within drug discovery, discrete workflows like hit identification, lead optimization, preclinical research, and target validation impose specific sampling cadence, aliquot sizing, and integrity monitoring needs. Finally, automation level differentiates buyer readiness: organizations opting for fully automated systems invest in end-to-end digital workflows and higher upfront capital for long-term efficiency, while manual and semi-automated systems remain prevalent where flexibility, lower capital expenditure, or unique sample types preclude full automation. Understanding these intersecting segments enables vendors and users to align solution features, service levels, and pricing strategies to real operational requirements.

How regional scientific ecosystems and regulatory environments influence compound management priorities, support models, and adoption of automation across global markets

Regional dynamics shape how organizations prioritize investments, partnerships, and operational resilience in compound management. In the Americas, a concentration of large pharmaceutical R&D hubs and mature biotech ecosystems drives demand for high-throughput, validated systems and service models that support regulated development. This region also features a strong aftermarket for integration services and localized support networks, encouraging vendors to offer long-term service agreements and customization options. Europe, the Middle East & Africa presents a diverse landscape where multinationals operate alongside national research institutes and an emerging biotech sector; regulatory harmonization across parts of Europe contrasts with localized procurement rules elsewhere, shaping adoption curves for automation and advanced inventory systems. In this region, interest in compliance-ready, modular solutions is pronounced given the need to balance cross-border collaboration with local regulatory constraints.

Asia-Pacific remains characterized by rapid capacity expansion, significant investment in translational and clinical research, and energetic growth of biotech startups that often demand flexible, scalable compound management solutions. The supply chain footprint in this region also fosters manufacturing and component sourcing opportunities, which can lower lead times for certain equipment. Across all regions, variations in labor costs, regulatory complexity, and infrastructure maturity influence the choice between fully automated and semi-automated or manual approaches, and they create opportunities for differentiated service offerings such as remote diagnostics, regional spare parts inventories, and localized validation support.

Competitive dynamics and partnership trends revealing how hardware-software-service integration and application-focused innovation are shaping vendor differentiation and customer retention

Key company insights focus on strategic positioning, partnership models, and the areas where competitive differentiation is emerging. Market leaders that pair robust hardware portfolios with scalable software platforms and proven service delivery are best positioned to capture enterprise-level programs requiring long-term validation and uptime guarantees. Conversely, emerging vendors find traction by offering modular, upgradeable architectures that lower the barrier to automation for midsized laboratories and by emphasizing interoperability through open APIs that facilitate integration with laboratory information management systems. Strategic partnerships between instrument manufacturers, software providers, and third-party service organizations are increasingly common as companies seek to deliver end-to-end value propositions covering installation, validation, maintenance, and data management.

Additionally, some firms are investing in application-specific solutions that address the unique demands of biologics and cell and gene therapies, including temperature-controlled logistics and contamination control innovations. Service differentiation is also notable: providers that can offer rapid on-site support, predictive maintenance remotely enabled by IoT sensors, and tailored training for in-house technical staff tend to reduce downtime and build stronger customer retention. Finally, companies that demonstrate a commitment to sustainability through energy-efficient storage systems and consumable reduction initiatives are resonating with institutional buyers seeking to meet environmental and governance objectives.

Actionable strategic priorities for executives to strengthen interoperability, supply resilience, and data-driven operations in compound management environments

Industry leaders should take decisive actions to align compound management capabilities with scientific strategy and operational resilience. First, executives should prioritize interoperability and modularity when evaluating new equipment, ensuring that investments can be scaled or repurposed as scientific priorities change. Second, cross-functional governance structures that include procurement, scientific operations, quality, and IT should be established to streamline supplier qualification, manage tariff and supply chain risk, and enforce data integrity standards. Third, organizations should pilot data-rich initiatives that use analytics and IoT-enabled diagnostics to reduce unplanned downtime and optimize reagent utilization, thereby simultaneously improving throughput and lowering operational risk.

Moreover, leaders ought to assess their portfolio of suppliers and service agreements through scenario planning that accounts for regional sourcing variability and potential policy shifts. Investing in staff training and in-house validation capabilities will reduce dependency on external service providers and accelerate time-to-experiment. Finally, sustainability and compliance should be elevated as strategic imperatives; adopting energy-efficient storage technologies, reducing single-use plastic consumption where feasible, and documenting chain-of-custody practices will both reduce cost pressure over time and align the organization with evolving stakeholder expectations.

A rigorous mixed-methods approach combining practitioner interviews, technical literature review, and expert validation to derive practical operational insights and strategic recommendations

The research methodology underpinning this executive summary combined a structured review of primary and secondary inputs with expert validation to ensure relevance and practical applicability. Primary sources included interviews with laboratory managers, procurement heads, and technical leads across academic, biotech, contract research, government, and pharmaceutical organizations to capture firsthand operational challenges and procurement behaviors. Secondary inputs encompassed vendor technical literature, regulatory guidance documents, and peer-reviewed publications that describe evolving handling requirements for small molecules and complex biologics, as well as white papers on automation and data integration best practices.

These inputs were synthesized using a thematic analysis approach to identify recurring pain points, adoption enablers, and value levers. Cross-validation with experienced technologists and supply chain specialists ensured that operational recommendations were grounded in real-world constraints and opportunities. Care was taken to anonymize sensitive contributor information, and all conclusions emphasize qualitative trends and actionable insights rather than quantitative market estimates, enabling leaders to apply findings directly to technology selection, process redesign, and vendor negotiations.

A forward-looking synthesis explaining why compound management is now a strategic enabler of research velocity, sample integrity, and regulatory readiness for R&D organizations

In conclusion, compound management has evolved from a largely transactional back-office function to a strategic capability that materially influences research velocity, data integrity, and regulatory readiness. Advancements in automation, the growing prominence of biologics and cell and gene therapies, and increasing emphasis on data-driven maintenance and inventory control are converging to raise the bar for system interoperability, environmental controls, and service reliability. Organizations that proactively align procurement, scientific operations, and IT functions will be better positioned to capture the productivity gains offered by modern compound management systems and to mitigate risks associated with supply chain volatility and regulatory scrutiny.

Moving forward, decision-makers should treat compound management as an integral component of their research platform strategy-investing in modular, validated systems where appropriate, strengthening supplier and regional risk management, and leveraging analytics to optimize uptime and reagent use. By doing so, laboratories and development organizations can improve throughput, safeguard sample integrity, and support the translational goals that drive scientific and commercial success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Compound Management Market, by End User

  • 8.1. Academic And Research Institutions
  • 8.2. Biotech Companies
  • 8.3. Contract Research Organizations
  • 8.4. Government And Regulatory Agencies
  • 8.5. Pharmaceutical Companies

9. Compound Management Market, by Compound Type

  • 9.1. Biologics
    • 9.1.1. Cell Therapy Products
    • 9.1.2. Gene Therapy Products
    • 9.1.3. Monoclonal Antibodies
    • 9.1.4. Recombinant Proteins
    • 9.1.5. Vaccines
  • 9.2. Nucleotides
  • 9.3. Peptides
  • 9.4. Small Molecules

10. Compound Management Market, by Application

  • 10.1. Agrochemicals
  • 10.2. Drug Discovery
    • 10.2.1. Hit Identification
    • 10.2.2. Lead Optimization
    • 10.2.3. Preclinical Research
    • 10.2.4. Target Validation
  • 10.3. Material Science
  • 10.4. Specialty Chemicals

11. Compound Management Market, by Automation Level

  • 11.1. Fully Automated Systems
  • 11.2. Manual Systems
  • 11.3. Semi Automated Systems

12. Compound Management Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Compound Management Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Compound Management Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Compound Management Market

16. China Compound Management Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agilent Technologies, Inc.
  • 17.6. Arctoris Ltd.
  • 17.7. AXXAM S.p.A.
  • 17.8. Azenta US, Inc.
  • 17.9. Beckman Coulter Life Sciences
  • 17.10. BioAscent Discovery Ltd.
  • 17.11. BioIVT
  • 17.12. Biosero Inc.
  • 17.13. Brooks Automation, Inc.
  • 17.14. ChemBridge Corporation
  • 17.15. ChemDiv Inc.
  • 17.16. Collaborative Drug Discovery
  • 17.17. Compound Management Group
  • 17.18. Danaher Corporation
  • 17.19. Evotec SE
  • 17.20. Hamilton Company
  • 17.21. HighRes Biosolutions Inc.
  • 17.22. Labcyte Inc.
  • 17.23. LiCONiC AG
  • 17.24. OpenEye Scientific Software, Inc.
  • 17.25. PerkinElmer, Inc.
  • 17.26. SPT Labtech Ltd.
  • 17.27. Tecan Group Ltd.
  • 17.28. Titian Service Limited
  • 17.29. Wuxi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COMPOUND MANAGEMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COMPOUND MANAGEMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES COMPOUND MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA COMPOUND MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY GOVERNMENT AND REGULATORY AGENCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY GOVERNMENT AND REGULATORY AGENCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY GOVERNMENT AND REGULATORY AGENCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY CELL THERAPY PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY CELL THERAPY PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY CELL THERAPY PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY GENE THERAPY PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY GENE THERAPY PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY GENE THERAPY PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY NUCLEOTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY NUCLEOTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY NUCLEOTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY AGROCHEMICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY AGROCHEMICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY AGROCHEMICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY HIT IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY HIT IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY HIT IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY PRECLINICAL RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY PRECLINICAL RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY PRECLINICAL RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY TARGET VALIDATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY TARGET VALIDATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY TARGET VALIDATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY MATERIAL SCIENCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY MATERIAL SCIENCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY MATERIAL SCIENCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY SPECIALTY CHEMICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY SPECIALTY CHEMICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY SPECIALTY CHEMICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY FULLY AUTOMATED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY FULLY AUTOMATED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY FULLY AUTOMATED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY MANUAL SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY MANUAL SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY MANUAL SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY SEMI AUTOMATED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY SEMI AUTOMATED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY SEMI AUTOMATED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS COMPOUND MANAGEMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA COMPOUND MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA COMPOUND MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA COMPOUND MANAGEMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE COMPOUND MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST COMPOUND MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA COMPOUND MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC COMPOUND MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN COMPOUND MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 148. GCC COMPOUND MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GCC COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. GCC COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. GCC COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 152. GCC COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. GCC COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 154. GCC COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION COMPOUND MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS COMPOUND MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 169. G7 COMPOUND MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. G7 COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. G7 COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. G7 COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 173. G7 COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. G7 COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 175. G7 COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 176. NATO COMPOUND MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. NATO COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. NATO COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. NATO COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 180. NATO COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. NATO COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 182. NATO COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL COMPOUND MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES COMPOUND MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA COMPOUND MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA COMPOUND MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA COMPOUND MANAGEMENT MARKET SIZE, BY COMPOUND TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA COMPOUND MANAGEMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA COMPOUND MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA COMPOUND MANAGEMENT MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA COMPOUND MANAGEMENT MARKET SIZE, BY AUTOMATION LEVEL, 2018-2032 (USD MILLION)